

November 10, 2025

To,
National Stock Exchange of India Limited
Exchange Plaza, C-1,
Block- G, Bandra – Kurla Complex,
Bandra (East), Mumbai – 400051
Symbol: AAKAAR

Dear Sir/ Madam,

Ref.: **Outcome of the Board Meeting in accordance with the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015.**

Pursuant to Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations') as amended, and other applicable provisions, the Board of Directors of the Company ('the Board'), at its Meeting held today, i.e., Monday, November 10, 2025, has inter alia considered and approved:

1. Financial Results

Approved the Unaudited Financial Results of the Company, for the half year ended on September 30, 2025, as reviewed by the Audit Committee. In this regard, please find enclosed Unaudited Financial Results of the Company for the half year ended September 30, 2025. The said results are also being uploaded on the website of the company viz. www.akaarmedical.in

2. M/s. C.B. Mehta & Associates Chartered Accountants, Statutory Auditors of Company, have issued the Limited Review Report of the Financial Results on the above-mentioned results with unmodified opinion.

The Meeting of the Board of Directors of the Company commenced at 2.30 P.M. IST and concluded at 2.48 P.M. IST

You are requested to disseminate the above information on your website.

Yours truly,
For **Aakaar Medical Technologies Ltd.**

Anoopkumar V. Pillai
Company Secretary & Compliance Officer

Encl: As above.

**AAKAAR MEDICAL TECHNOLOGIES LIMITED**

(Formerly known as AAKAAR MEDICAL TECHNOLOGIES PRIVATE LIMITED)

Registered Address: A-801, Heritage Plaza, Teli Gali, Cross Road, Andheri (E), Mumbai 400069

CIN : L74900MH2013PLC244717

Statement of Unaudited Standalone Financial Results for the half year ended September 30, 2025

(Amount in lacs except EPS)

Particulars	For the half year ended Sept 30, 2025 (Unaudited)	For the half year ended Sept 30, 2024 (Unaudited)	For the year ended Mar 31, 2025 (Audited)
I Revenue from operations	2,532.49	2,770.43	6,158.28
II Other income	29.71	6.77	17.79
III Total income (I + II)	2,562.21	2,777.19	6,176.07
IV Expenses:			
Cost of material consumed	42.66	162.63	353.03
Purchases of Stock-in-Trade	1,557.51	1,212.04	2,306.94
Changes in inventories of Stock-in-Trade and finished goods	(455.71)	(74.05)	(37.48)
Employee benefit expense	726.40	645.04	1,290.26
Finance costs	104.07	80.26	170.94
Depreciation and amortisation expenses	4.91	5.82	12.48
Other expenses	684.70	682.28	1,268.55
Total expenses	2,664.54	2,714.02	5,364.71
V Profit before tax (III-IV)	(102.33)	63.17	811.36
VI Prior period items			-
VII Tax expense:			
Current tax expense for the year	(18.54)	17.96	192.61
Short/ (excess) provision	-	-	19.65
Deferred tax expenses	(5.38)	(1.28)	(4.17)
	(23.93)	16.68	208.09
VIII Profit/ (Loss) for the period (V-VI-VII)	(78.41)	46.49	603.27
IX Earnings per equity share (EPS):			
Basic	(0.63)	0.50	6.12
Diluted	(0.63)	0.50	6.12
See accompanying Notes to Financial Results			

For and on behalf of
Aakaar Medical Technologies Limited

Dilip Meswani

Founder & Managing Director

DIN 06540985

Place: Mumbai

Date: November 10, 2025



CIN No.: L74900MH2013PLC244717

Aakaar Medical Technologies Limited
(formerly: Aakaar Medical Technologies Pvt.Ltd.)
A-801, Heritage Plaza, Teli Gali Cross Road
Andheri (East), Mumbai – 400 069 INDIA
Mob: + 91 9820317468
E-mail: info@aakaarmedical.in
www.aakaarmedical.in
GST No: 27AALCA7587Q1ZK

Notes to Unaudited Financial Results for Half Year ended September 30, 2025

1. The Financial Results are prepared in accordance with the Accounting Standards prescribed under Section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounting) Rules, 2014 (as amended) and other recognized accounting practices and policies as applicable.
2. The above results for the half year ended September 30, 2025 were reviewed by Audit Committee and were approved and taken on record by the Board of Directors in their meeting held on November 10, 2025.
3. Basic and Diluted EPS for the half year ended September 30, 2025 is calculated on the basis of 1,41,72,816 equity shares.
4. The Company operates through two segments viz. manufacturing and distribution of medical equipment and cosmetic medicines. Details of the same are as per the annexure attached.
5. Previous year figures have been regrouped / rearranged wherever necessary to correspond with the current year's classification / disclosures.
6. The details of utilization of IPO Proceeds of Rs. 2700.29 lakhs are as follows:

[Rs.in Lakhs]

Particulars	Proceeds	Utilisation upto 30th September, 2025	Unutilised upto 30th September, 2025
Working Capital	2,035.29	830.09	1,205.20
General Corporate Purpose	329.00	-	329.00
Issue expenses paid with GST	336.00	335.77	0.23
Total	2,700.29	1,165.86	1,534.43

For Aakaar Medical Technologies Limited

Dilip Meswani
Founder & Managing Director
DIN – 06540985

Place: Mumbai
Dated: November 10, 2025

S.No.	Particulars	As at 30th Sep, 2025	As at 30th Sep, 2024	As at 31st Mar, 2025
A	Segment Revenue			
	Aesthetic Devices & Device consumables	335	385	854.47
	Aesthetic Products	2197	2385.43	5303.6
	Total Revenue	2532.00	2770.43	6158.03
B	Result			
	Segment Profit/loss			
	Aesthetic Devices & Device consumables	167.5	192.5	469.96
	Aesthetic Products	976.96	1108.12	2152.53
	Segment Operating Profit	1387.54	1469.81	3535.54
	Reconciliation of segment operating profit to operating profit			
	Unallocated:			
	Employee Benefit Expense	726.4	645.04	1296.69
	Other Expense	689.11	688.1	1277.61
	Other miscellaneous expenses net of income	-29.71	-6.77	(17.78)
	Operating Profit	1.74	143.44	979.02
	Finance Costs	-104.07	-80.26	170.95
	Profit before tax	-102.33	63.18	808.07
C	Segment Assets			
	Aesthetic Devices & Device consumables	122.68	97.8	197.50
	Aesthetic Products	2526.72	2102.56	2410.91
	Unallocated Corporate Assets	4467.03	1896.71	2802.03
	Total Assets	7116.43	4097.07	5410.44
D	Segment Liabilities			
	Unallocated Corporate liabilities	2402.51	2666	3090.16
	Total Liabilities	2402.51	2666	3090.16

M

**AAKAAR MEDICAL TECHNOLOGIES LIMITED**

(Formerly known as AAKAAR MEDICAL TECHNOLOGIES PRIVATE LIMITED)

Registered Address: A-801, Heritage Plaza, Teli Gali, Cross Road, Andheri (E), Mumbai 400069

CIN : L74900MH2013PLC244717

Statement of Assets and Liabilities as at September 30, 2025

(Amount in Lacs)

Particulars	As at Sept 30, 2025 (Unaudited)	As at Mar 31, 2025 (Audited)
EQUITY AND LIABILITIES		
1 Equity		
Shareholders' funds		
(a) Share capital	1,417.28	1,042.24
(b) Reserves and surplus	3,296.64	1,283.58
	4,713.92	2,325.82
2 Liabilities		
Non-current liabilities		
(a) Long-term provisions	106.74	94.51
	106.74	94.51
Current liabilities		
(a) Short-term borrowings	1,711.57	2,273.83
(b) Trade payables		
Total outstanding dues of micro enterprises and small enterprises; and	119.26	3.11
Total outstanding dues of creditors other than micro enterprises and small enterprises	124.50	348.05
(c) Other current liabilities	238.74	284.10
(d) Short-term provisions	101.70	86.55
	2,295.77	2,995.64
	7,116.43	5,415.97
ASSETS		
1 Non-current assets		
(a) Property, Plant and Equipment and Intangible assets		
i. Property, Plant and Equipments	19.97	22.81
ii. Intangible assets	1.58	0.94
(b) Deferred tax assets (Net)	44.97	39.59
(c) Long term loans and advances	168.83	39.54
(d) Other non-current assets	1,691.82	129.54
	1,927.17	232.42
2 Current assets		
(a) Inventories	1,911.14	1,455.42
(b) Trade receivables	2,649.40	2,800.45
(c) Cash and bank balance	143.04	555.08
(d) Short term loans and advances	-	13.98
(d) Other current assets	485.70	358.62
	5,189.26	5,183.55
	7,116.43	5,415.97

See accompanying Notes to Financial Results

For and on behalf of
Aakaar Medical Technologies LimitedPlace: Mumbai
Date: November 10, 2025Dilip Meswani
Founder & Managing Director
DIN 06540985

**AAKAAR MEDICAL TECHNOLOGIES LIMITED**

(Formerly known as AAKAAR MEDICAL TECHNOLOGIES PRIVATE LIMITED)

Registered Address: A-801, Heritage Plaza, Teli Gali, Cross Road, Andheri (E), Mumbai 400069

CIN : L74900MH2013PLC244717

Statement of Cash Flows for the half year ended September 30, 2025

(Amount in Lacs)

Particulars	For the half year ended Sept 30, 2025 (Unaudited)	For the year ended Mar 31, 2025 (Audited)
A. Cash flow from operating activities		
Net Profit / (Loss) before tax	(102.33)	811.37
Adjustments for:		
Depreciation and amortisation	4.91	12.48
Interest income	(29.14)	(1.31)
Balance written back	-	(1.83)
Share based payment expenses	-	1.60
Sundry balances written off	0.41	3.23
Foreign exchange gain/ loss	12.75	(13.47)
Finance costs	99.59	157.71
Operating profit / (loss) before changes in operating assets	(13.81)	969.78
Changes in Operating Assets:		
Adjustments for (increase) / decrease in operating assets:		
(Increase)/ Decreases in trade receivables	150.64	(1,177.43)
(Increase)/ Decreases in inventories	(455.71)	(37.48)
(Increase)/ Decreases in other assets	(131.05)	(245.31)
(Increase)/ Decreases in loans and advances	41.95	(41.95)
Increase/ (Decrease) in trade payables	(120.16)	184.77
Increase/ (Decrease) in short term provisions	15.15	2.75
Increase/ (Decrease) in long term provisions	12.23	11.48
Increase/ (Decrease) in other current liabilities	(45.37)	(8.46)
Cash generated from operations	(546.13)	(341.85)
Net income tax (paid) / refunds received	(138.72)	(198.77)
Net cash flow used in operating activities	(684.85)	(540.62)
B. Cash flow from investing activities		
Purchase of fixed asset	(2.70)	(8.39)
Interest received	6.80	0.46
Term deposits	(1,535.52)	2.53
Net cash flow used in investing activities	(1,531.42)	(5.40)
C. Cash flow from financing activities		
Proceeds from cash credit/ overdraft facility	(397.15)	1,022.76
Net Increase / (Decrease) of borrowings	(165.10)	(254.60)
Proceeds from issue of shares	2,700.29	525.67
Share issue expenses	(233.78)	(65.11)
Finance cost	(99.59)	(157.71)
Net cash flow generated from financing activities	1,804.67	1,071.01
Net decrease in Cash and cash equivalents (A+B+C)	(411.60)	524.99
Cash and cash equivalents at the beginning of the year	554.64	29.65
Cash and cash equivalents at the end of the year	143.04	554.64
Components of cash and cash equivalents		
Balance with banks and cash on hand	143.04	554.64
	143.04	554.64
See accompanying Notes to Financial Results		

For and on behalf of
Aakaar Medical Technologies Limited

Dilip Meswani

Founder & Managing Director
DIN 06540985Place: Mumbai
Date: November 10, 2025

Independent Auditor's Review Report on Unaudited Standalone Half Yearly Financial Results of Aakaar Medical Technologies Limited in pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To,

The Members of Aakaar Medical Technologies Limited
(formerly known as Aakaar Medical Technologies Private Limited)

1. We have reviewed the accompanying statement of unaudited standalone financial results of Aakaar Medical Technologies Limited ("The Company") for the half year ended September 30, 2025 ("the statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. The preparation of the statement, which is the responsibility of the Company's Management and approved by the Board of Directors, in accordance with the recognition and measurement principles laid down in Accounting Standard 25, (AS 25) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'). Our responsibility is to issue a report on these financial statements based on our review.
3. We conducted our review of the statements in accordance with Standards on Review Engagement (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited Standalone financial result prepared in accordance with the recognition and measurement principles laid down in the aforesaid Accounting Standards (AS) specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of the Regulation, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For C.B. Mehta and Associates
Chartered Accountants
FRN 124978W

C.B. Mehta
Proprietor
MRN 116543



Place: Mumbai

Date: November 10, 2025

UDIN: 25116543BMJPY17951